BioWorld

Aug. 1, 2006

View Archived Issues

Predix In Potential $307.5M Collaboration With Amgen

In its first major partnership, Predix Pharmaceuticals Holdings Inc. could receive more than $307.5 million per terms of a new deal with Amgen Inc. on S1P1 modulators for autoimmune diseases. (BioWorld Today) Read More

YM Secures Japanese Partner For EGFR-Inhibitor In Cancer

Read More

Still Turning: Racial Profiling, Harassment, VC Execs Get Hip

Read More

Pandemic Planning: Not 'Out Of The Woods' Despite Good News

Read More

FDA Mulling Plan B OTC Sales For Those 18, Older

Read More

Opting For An LSE Listing, Napo Raises £11.9M In IPO

Read More

Receptor BioLogix Acquires Failed Aphton Cancer Drug

Read More

Other News To Note

Read More